Cascadian Therapeutics (CASC) saw its loss narrow to $11.40 million, or $0.30 a share for the quarter ended Mar. 31, 2017. In the previous year period, the company reported a loss of $12.89 million, or $0.81 a share. The company has not recorded any revenues for the current as well as previous quarter.
Operating loss for the quarter was $11.56 million, compared with an operating loss of $12.97 million in the previous year period.
"In the first quarter, we continued to build a solid management team and the financial foundation that will help us execute our core objectives over the next several years,” said Scott Myers, president and chief executive officer of Cascadian Therapeutics. "We are focused on enrolling HER2CLIMB, our pivotal study of tucatinib in combination for late-stage HER2-positive metastatic breast cancer for patients with and without brain metastases. We are very pleased with the current pace of enrollment and are expanding HER2CLIMB globally."
Disclaimer: Please note that this is an auto-generated article. IRIS does not guarantee the accuracy, adequacy or completeness of any information and is not responsible for any errors or omissions or for the results obtained from the use of such information. IRIS especially states that it has no financial liability whatsoever to any user on account of the use of information provided on its website. For queries contact: [email protected]
